OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol diabetes and skin care, has told DirectorsTalk about a new patent filing. The filing protects
OptiBiotix Health’s Stephen O’Hara discusses their new strategy and what this will mean for investors in this exclusive interview with DirectorsTalk
OptiBiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about it’s new strategy, the thinking behind this, what it means for shareholders and when we can expect to see
Stephen O’Hara, CEO of OptiBiotix PLC LON:OPTI, commented: “The rapid developments in the understanding of the microbiome have been matched by Optibiotix’s own progress in a number of key but
An article recently published by This is Money singled out a handful of pharmaceutical companies including Motif Bio Plc (LON:MTFB) and Optibiotix Health plc (LON:OPTI) as good small cap ideas.
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, has told DirectorsTalk about a new patent filing. The filing protects advances made in OptiBiotix’s skin division in identifying microbial proteins which have the potential to prevent
Last week news was announced that the White House is announcing the launch of the National Microbiome Initiative (NMI). It’s an ambitious plan to better understand the microbes that live
OptiBiotix Health PLC (LON:OPTI) CEO Stephen OHara caught up with DirectorsTalk to share his thoughts on an article discussing Why Pharma Insiders Are Betting £100m On “the Microbiome”. The article
OptiBiotix Health Plc (LON:OPTI) a life sciences company developing a range of products to modify the human microbiome has known for some time the huge market potential that surrounds it’s
Stephen O’Hara, CEO of OptiBiotix Health PLC LON:OPTI, commented: “I am delighted with the strong progress OptiBiotix has made in our first full year of trading on AIM. In a
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
